Results 121 to 130 of about 2,472,934 (283)

A Structured Benefit-Risk Assessment Operating Model for Investigational Medicinal Products in the Pharmaceutical Industry. [PDF]

Ther Innov Regul Sci, 2023
Sullivan T, Zorenyi G, Feron J, Smith M, Nord M.   +4 more
europepmc   +1 more source

Ares Project Technology Assessment: Approach and Tools [PDF]

, 2010
Technology assessments provide a status of the development maturity of specific technologies. Along with benefit analysis, the risks the project assumes can be quantified. Normally due to budget constraints, the competing technologies are prioritized and
Hueter, Uwe, Tyson, Richard
core   +1 more source

Regulatory benefit-risk assessment

, 2013
De beoordeling van nieuwe geneesmiddelen is erop gericht alleen veilige, effectieve en kwalitatief hoogwaardige geneesmiddelen toe te laten tot de markt. UMCG-promovendus Arna Arnardóttir onderzocht hoe registratieautoriteiten een passend evenwicht vinden tussen voordelen en risico’s.
openaire   +1 more source

Next‐generation proteomics improves lung cancer risk prediction

Molecular Oncology, EarlyView.
This is one of very few studies that used prediagnostic blood samples from participants of two large population‐based cohorts. We identified, evaluated, and validated an innovative protein marker model that outperformed an established risk prediction model and criteria employed by low‐dose computed tomography in lung cancer screening trials.
Megha Bhardwaj, Clara Frick, Ben Schöttker, Bernd Holleczek, Hermann Brenner   +4 more
wiley   +1 more source

Total mercury and fatty acids content in selected fish marketed in Quito - Ecuador. A benefit-risk assessment. [PDF]

Toxicol Rep, 2023
Yánez-Jácome GS, Romero-Estévez D, Vélez-Terreros PY, Navarrete H.   +3 more
europepmc   +1 more source

Monitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer

Molecular Oncology, EarlyView.
Monitoring circulating tumor DNA (ctDNA) in patients with operable breast cancer can reveal disease relapse earlier than radiology in a subset of patients. The failure to detect ctDNA in some patients with recurrent disease suggests that ctDNA could serve as a supplement to other monitoring approaches.
Kristin Løge Aanestad, Marie Austdal, Oddmund Nordgård, Gunnar Mellgren, Satu Oltedal, Marie L. Austbø, Ylva H. Vignes, Thomas Helland, Kristin Jonsdottir, Tone H. Lende, Emilius A. M. Janssen, Bjørnar Gilje, Kjersti Tjensvoll, PBCB study group, Gunnar Mellgren, Tone Hoel Lende, Anette Heie, Kristin Viste, Anita Røyneberg Alvheim, Emiel AM Janssen, Kristin Jonsdottir, Ann Cathrine Kroksveen, Thomas Helland, Einar Gudlaugsson, Oddmund Nordgård, Satu Oltedal, Kristin Løge Aanestad, Jan Terje Kvaløy, Kirsten Lode, Kari Britt Hagen, Marie Austdal, Ylva H. Vignes, Siri Tungland Sola, Nina Egeland Amundsen, Finn Magnus Eliassen, Emeritus Ernst A Lien   +35 more
wiley   +1 more source

Benefit-Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness. [PDF]

J Am Heart Assoc, 2022
Raskob GE, Ageno W, Albers G, Elliott CG, Halperin J, Maynard G, Steg PG, Weitz JI, Albanese J, Yuan Z, Levitan B, Lu W, Suh EY, Spiro T, Lipardi C, Barnathan ES, Spyropoulos AC.   +16 more
europepmc   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

Risk-benefit assessment of ivabradine in the treatment of chronic heart failure

Drug, Healthcare and Patient Safety, 2014
Irmina Urbanek, Krzysztof Kaczmarek, Iwona Cygankiewicz, Pawel PtaszynskiDepartment of Electrocardiology, Chair of Cardiology and Cardiosurgery, Medical University, Lodz, PolandAbstract: Heart rate is not only a major risk marker in heart failure but ...
Urbanek I, Kaczmarek K, Cygankiewicz I, Ptaszynski P   +3 more
doaj  

Structured Benefit-Risk Assessment of a New Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Individuals Ages 12 Months and Older. [PDF]

Infect Dis Ther, 2023
Neveu D, Mallett Moore T, Zambrano B, Chen A, Kürzinger ML, Marcelon L, Singh Dhingra M.   +6 more
europepmc   +1 more source